Company intelligence / Profile preview

Alyea Therapeutics

Nevada, United States

Ownership: Private
Development stage: Other

Overview

Lead asset—low-dose naltrexone (JAN123)—is progressing to pivotal Phase 3 trial for Complex Regional Pain Syndrome, having received FDA Orphan Drug Designation and pursuing the 505(b)(2) regulatory pathway. Clinical programs aim to demonstrate efficacy and safety for non-addictive, non-opioid pain relief, but published pivotal results are not yet available.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

Alyea Clear Patch

Preclinical

Beyond the preview

Go deeper on Alyea Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alyea Therapeutics.

Explore the full profile